Last updated on January 2020

Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options

Brief description of study

A study to evaluate F901318 (study drug) for the treatment of invasive fungal infections in patients lacking suitable alternative treatment options.

Detailed Study Description

This is the first study in patients of F901318. Patients with a limited treatment options will be enrolled and treated with F901318 (olorofim) for up to 12 weeks.

Clinical Study Identifier: NCT03583164

Find a site near you

Start Over

Royal Melbourne Hospital

Melbourne, Australia
  Connect »

The Alfred Hospital

Melbourne, Australia
  Connect »